He describes how Metsera is aiming to develop a differentiated GLP-1 vs currently marketed products by having a lower dose and longer half-life. We discuss all the hot button issues.
Share this post
Metsera's CEO Whit Bernard on the obesity…
Share this post
He describes how Metsera is aiming to develop a differentiated GLP-1 vs currently marketed products by having a lower dose and longer half-life. We discuss all the hot button issues.